293 related articles for article (PubMed ID: 30339193)
1. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
3. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
[TBL] [Abstract][Full Text] [Related]
4. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
[TBL] [Abstract][Full Text] [Related]
5. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
6. Clinical implementation of circulating tumour DNA testing for
Spence T; Perera S; Weiss J; Grenier S; Ranich L; Shepherd F; Stockley TL
J Clin Pathol; 2021 Feb; 74(2):91-97. PubMed ID: 32471890
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
[TBL] [Abstract][Full Text] [Related]
8. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
9. Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva.
Tu M; Cheng J; Chen YL; Jea WC; Chen WL; Chen CJ; Ho CL; Huang WL; Lin CC; Su WC; Ye Q; Deignan J; Grody W; Li F; Chia D; Wei F; Liao W; Wong DTW; Strom CM
J Mol Diagn; 2020 Aug; 22(8):1050-1062. PubMed ID: 32497715
[TBL] [Abstract][Full Text] [Related]
10. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
11. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
12. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
[TBL] [Abstract][Full Text] [Related]
13. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Ma Y; Shi H; Du Y; Huang Y
Sci Rep; 2018 Oct; 8(1):15426. PubMed ID: 30337598
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.
Zhu L; Zhang S; Xun Y; Jiang Y; Xia B; Chen X; Wang L; Jiang H; Ma S
Pathol Oncol Res; 2018 Oct; 24(4):843-851. PubMed ID: 28868565
[TBL] [Abstract][Full Text] [Related]
16. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
19. Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer.
Mirtavoos-Mahyari H; Ghadami M; Khosravi A; Esfahani-Monfared Z; Seifi S; Motevaseli E; Pourabdollah M; Modarressi M
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3591-3596. PubMed ID: 31870098
[TBL] [Abstract][Full Text] [Related]
20. Exosome-Based Detection of
Castellanos-Rizaldos E; Grimm DG; Tadigotla V; Hurley J; Healy J; Neal PL; Sher M; Venkatesan R; Karlovich C; Raponi M; Krug A; Noerholm M; Tannous J; Tannous BA; Raez LE; Skog JK
Clin Cancer Res; 2018 Jun; 24(12):2944-2950. PubMed ID: 29535126
[No Abstract] [Full Text] [Related]
[Next] [New Search]
